INTRODUCTION {#s1}
============

Head and neck cancer (HNC) is one of the most prevalent cancers worldwide \[[@R1]--[@R3]\]. The standard treatment for patients with HNC is surgery, radiation or chemotherapy or a combination of these treatments \[[@R2]--[@R4]\]. Although treatment strategies have advanced in the last two decades, the overall 5-year survival rate for patients has not significantly changed \[[@R3]--[@R5]\]. Local recurrence after radiotherapy is a major obstacle to recovery in HNC \[[@R3]--[@R5]\]. It is essential to elucidate the mechanisms underlying this disease to develop a more effective therapeutic modality. To obtain a more complete profile of the molecules that contribute to radioresistance, we previously established several sublines derived from HNC cell lines with highly radioresistant phenotypes \[[@R6], [@R7]\]. The cDNA microarray method was used for transcriptomic profiling of nasopharyngeal cancer cell lines \[[@R6]\], and comparative proteomic analysis was performed to search for potential proteins in oral cancer cells associated with radioresistance \[[@R7]\]. GDF15 was highly expressed in various radioresistant sublines by both screening methods. These results suggest that GDF15 may play a crucial role in the regulation of radio-sensitivity in HNC. However, the underlying mechanism by which this molecule leads to radioresistance remains unclear.

GDF15 (growth differentiation factor 15), also known as MIC-1, PLAB, P-TGFβ, PDF, and HP00269, was discovered and cloned simultaneously by separate groups \[[@R8], [@R9]\]. GDF15 is expressed as a 40 kDa propeptide that is cleaved in the endoplasmic reticulum to release a 25 kDa dimeric protein in circulation \[[@R8]--[@R10]\]. GDF15is a TGF-β/bone morphogenetic protein (BMP) super-family member that is expressed in a wide range of tissues, indicating that this molecule has broad biological activity \[[@R9]--[@R10]\]. Similar to other TGF-β family member, GDF15 exhibits cytokine activity and is induced by cellular stress conditions and responds to microenvironment stimulators \[[@R9]--[@R10]\]. Recently, several studies have reported that GDF15 is dysregulated in cancers. For examples, GDF15 possesses pro-tumorigenic functions, as indicated by the high expression or secretion in many types of cancer tissues, including colorectal, gastric, esophageal, oral, pancreatic, liver, and ovarian cancers \[[@R11]--[@R26]\]. This elevated expression was often associated with more aggressive diseases \[[@R22]--[@R25]\]. However, tumor suppressive effects have been found in breast, bladder, and endothelial cancer cells \[[@R26]--[@R28]\]. Apparently, GDF15 has a complicated role during tumorigenesis, which may be dependent on the specific tissues or disease conditions.

In the present study, we determined whether and how GDF15 contributes to radioresistance in HNC. We found that GDF15 contributes to radioresistance and facilitates cancer stemness conversion through regulation of cellular reactive oxygen species (ROS) via a SMAD-associated pathway. These findings were also supported by a xenograft mouse study, which demonstrated that tumor with higher GDF15 exhibited significant resistance to radiation treatment. GDF15 may serve as a predictive marker of radioresistance and a sensitizing target for the treatment of refractory HNC.

RESULTS {#s2}
=======

GDF15 contributes to radioresistance by suppressing cellular reactive oxygen species (ROS) {#s2_1}
------------------------------------------------------------------------------------------

As GDF15 was found to be substantially overexpressed in various radioresistant sublines \[[@R6], [@R7]\], we confirmed whether GDF15 functionally contributes to radioresistance. In vitro gain-of-function experiments were performed by addition of recombinant human GDF15 (rhGDF15) protein to the culture medium. The potential effect on radiosensitivity was determined by clonogenic survival assays. The results are shown in Figure [1A](#F1){ref-type="fig"}. Administration of rhGDF15 significantly increased radioresistance in two HNC cell lines, with 1.3- to 1.7-fold increases in the number of surviving colonies at 4 Gy of irradiation. Loss-of-function experiments using GDF15-shRNA (GDF15sh) transfection were conducted. Silencing of GDF15 (Figure [1B](#F1){ref-type="fig"}) sensitized cells to irradiation, by reducing colony survival to 66-72% in two HNC cell lines (Figure [1C](#F1){ref-type="fig"}). Nevertheless, modulation of GDF15 had a minimal effect on cell growth in all tested cell lines (Figure [1D](#F1){ref-type="fig"}). These results suggested that GDF15 protects cells against radiation treatment and contributes to radioresistance.

![GDF15 contributes to cancer cell radioresistance but not cell growth\
**A.** Administration of rhGDF15 led to radioresistance in two HNC cell lines. Detroit and KB cells were treated with 20 ng/ml rhGDF15 for 5 days and then subjected to various doses of irradiation (0, 2, and 4 Gy). Fourteen days later, the cell colonies were determined by staining with 0.05% crystal violet (n=3). **B.** GDF15 expression was successfully inhibited after transfection of GDF15-specific shRNA plasmids (GDF15sh) in KB and OECM1 cell lines. After 48 h, cells were harvested for western blot analysis. **C.** Silencing GDF15 sensitized cells to irradiation in HNC cells. OECM1 and KB cells were transfected with GDF15sh or the vector plasmids and then subjected to irradiation (0 to 6 Gy). After 14 days, the cell colonies were determined (n=3). **D.** GDF15 had minimal effect on growth regulation in HNC cells. The OECM1, Detroit and KB cells were treated with or without rhGDF15 (20 ng/ml for 5 days). After 14 days, the cell colonies were determined (n=3). (\*: *p* \<0.05, *n.s.*: non-significance, *t*-test).](oncotarget-08-1508-g001){#F1}

It is well established that ionizing radiation can induce ROS in the cell, leading to apoptosis \[[@R29]\]. Therefore, we determined whether GDF15 promotes radioresistance through regulation of cellular ROS levels. The intracellular ROS were measured using the H~2~DCF-DA oxidation method, and the green fluorescence DCF product was analyzed by flow cytometry \[[@R7]\]. Administration of rhGDF15 reduced intracellular ROS levels to 47-68% in two HNC cell lines (Figure [2A](#F2){ref-type="fig"}). GDF15 silencing increased ROS production by 1.3- to 1.9-fold in HNC cells (Figure [2B](#F2){ref-type="fig"}). This phenomenon was observed in esophageal cancer cells as well. The radiation-induced ROS generation was substantially higher in GDF15-silenced cells as determined by the green fluorescence using DCF staining in two cell lines (Figure [2C](#F2){ref-type="fig"}). These data suggest that GDF15 has a role in the suppression of ROS generation. We further determined whether mitochondria, the most common source of ROS generation, were disturbed by GDF15. The MitoCapture assay was used to detect the disruption of mitochondrial membrane permeability, which may lead to cell apoptosis \[[@R30]\]. The kit utilizes a cationic dye that fluoresces differently in healthy (red fluorescence) and in apoptotic (green fluorescence) cells using flow cytometry. As shown in Figure [2D](#F2){ref-type="fig"}, GDF15 silencing increased the fraction of apoptotic cells (FITC population) by 1.3- to 1.9-fold in two HNC cell lines, suggesting that GDF15 knockdown decreased mitochondrial membrane potential and led to apoptosis.

![GDF15 suppresses the intracellular reactive oxygen species levels by altering the mitochondrial membrane potential\
**A.** Administration of rhGDF15 suppressed intracellular ROS level in HNC cells. KB and OECM1 cells were treated with 20 ng/ml of rhGDF15 for 5 days. After staining with DCF dye, the cells were subjected to flow cytometric analysis to determine the intracellular ROS levels. All values are presented as fluorescence intensity. **B.** GDF15 silencing increased ROS production in HNC cells. After transfection with GDF15sh or the vector plasmids, the KB and OECM1 cells were stained with DCF dye and subjected to flow cytometric analysis. **C.** GDF15 silencing increased ROS production in esophageal cancer cells. CE48T/VGH and CE81T/VGH cells were co-transfected with DsRed and GDF15sh/vector plasmids and then subjected to 4 Gy of irradiation. After staining with DCF dye, the cells were subjected to confocal microscopy. **D.** GDF15 silencing reduced mitochondrial membrane potential and led to apoptosis in HNC cells. KB or Detroit cells were transfected with the GDF15sh or the vector plasmids for 48 h. After incubating with MitoCapture reagents, the cells were subjected to flow cytometry analysis. The PE fluorescence fraction represents healthy cells, and the FITC fraction represents apoptotic cells.](oncotarget-08-1508-g002){#F2}

Taken together, these results suggest that GDF15 promotes radioresistance through suppression of intracellular ROS production, which may involve the increase of mitochondria membrane potential. Silencing of GDF15 resulted in ROS generation, which led to induction of cell apoptosis and increased radiosensitivity.

GDF15 promotes cancer stemness via facilitation of CD44+ and ALDH1+ cell populations {#s2_2}
------------------------------------------------------------------------------------

As radioresistance is a characteristic of cancer stem cells \[[@R31]\], we examined whether GDF15 also plays a role in cancer stemness. Because CD44+ and ALDH1+ have been characterized as markers of HNC stem cells \[[@R32], [@R33]\] we also determined the potential association between GDF15 levels and the CD44+- and ALDH1+-enriched populations. The CD44+ or ALDH1+ cell population was isolated by fluorescence-activated cell sorting (FACS) analysis, and the level of GDF15 expression was determined. GDF15 expression was increased in CD44+-enriched cells by 1.9- to 2.4-fold compared to the CD44- populations in two HNC cell lines (Figure [3A](#F3){ref-type="fig"}). Also, the secreted GDF15 was significantly higher in the conditional medium of the CD44+ cultured cells, with a 2.5- to 10-fold elevation as determined by ELISA (Figure [3B](#F3){ref-type="fig"}). For the ALDH+-enriched cells, GDF15 expression was increased by 2.8- to 5.7-fold compared to the ALDH1- populations in two HNC cell lines (Figure [3C](#F3){ref-type="fig"}). Concomitantly, these ALDH1+-enriched cells also showed higher CD44+ levels (Figure [3D](#F3){ref-type="fig"}). These results suggest that GDF15 expression was positively associated with the CD44+ and ALDH1+ populations in HNC.

![GDF15 promotes cancer stemness via facilitation of CD44+ and ALDH1+ cell populations\
**A.** Elevation of GDF15 mRNA expressions in CD44+ sorted cells compared to the CD44- cells in both KB and OECM1 cell lines, as determined by RT-PCR method (n=3). **B.** Elevation of GDF15 protein levels in the conditional medium of CD44+ sorted cells compared to the CD44- cells in both KB and OECM1 cell lines, as determined by ELISA method (n=3). **C.** Elevation of GDF15 mRNA expressions in ALDH1+ sorted cells compared to the ALDH1- cells in both KB and OECM1 cell lines, as determined by RT-PCR method (n=3). **D.** Elevation of CD44 mRNA expressions in ALDH1+ sorted cells compared to the ALDH1- cells in both KB and OECM1 cell lines, as determined by RT-PCR method (n=3). **E.** Elevation of CD44+ population in rhGDF15 treated cells compared to non-treated cells in both KB and Detroit cell lines, as determined by FACS method. **F.** Reduction of CD44+ population in GDF15sh transfected cells in both KB and Detroit cell lines, as determined by FACS method. **G.** Elevation of ALDH1+ population in rhGDF15 treated cells in both KB and Detroit cell lines, as determined by FACS method. **H.** Reduction of ALDH1+ population in GDF15sh transfected cells in both KB and Detroit cell lines, as determined by FACS method. **I.** Enhancement of spheroid cell formation in the GDF15+ sorted cells compared to GDF15- cells in both KB and OECM1 cell lines (n=3). **J.** Reduction of spheroid cell formation in GDF15sh transfected cells in both Detroit and KB cell lines (n=3). **K.** Increase of invasion ability in the rhGDF15 treated cells compared to non-treated cells (control) in both Detroit and KB cell lines (n=3). **L.** Increase of migration ability in the rhGDF15 treated cells compared to non-treated cells (control) in both Detroit and KB cell lines (n=3). (\*: *p*\<0.05, \*\*: *p*\<0.01, \*\*\*: *p*\<0.001, *n.s.*: non-significance, *t*-test).](oncotarget-08-1508-g003){#F3}

We next examined whether the CD44+ or ALDH1+ cell populations can be regulated by GDF15 by modulating the GDF15 levels via rhGDF15 or GDF15sh transduction. Administration of rhGDF15 increased the CD44+ populations by 1.3- to 4.2-fold in two HNC cell lines (Figure [3E](#F3){ref-type="fig"}). Conversely, GDF15 silencing reduced the CD44+ population to approximately 70% in HNC cells (Figure [3F](#F3){ref-type="fig"}). For the ALDH+ population, administration of rhGDF15 increased the ALDH1+ cell population by 1.3 to 7.7-fold (Figure [3G](#F3){ref-type="fig"}), whereas GDF15 silencing decreased this population to 17-69% in two cell lines (Figure [3H](#F3){ref-type="fig"}). These results suggest that GDF15 facilitated the CD44+ and ALDH1+ cell populations.

As self-renewal is a typical property of cancer stemness \[[@R31]--[@R33]\], we assessed this cellular characteristic in GDF15+ cells. FACS was used to isolate the GDF15+ sub-population from HNC cell lines. The GDF15+ cells showed enhanced spheroid cell formation compared to the GDF15- cells, as evidenced by the increased sphere size and number (3- to 6-fold increase) (Figure [3I](#F3){ref-type="fig"}). GDF15 silencing significantly suppressed spheroid cell formation to 53-59% in two HNC cell lines (Figure [3J](#F3){ref-type="fig"}). Furthermore, this molecular silencing substantially inhibited cellular migration (Figure [3K](#F3){ref-type="fig"}) and invasion (Figure [3L](#F3){ref-type="fig"}), attributes of cancer stemness \[[@R31]--[@R33]\]. Taken together, these data suggested that GDF15 promoted cancer stemness conversion by facilitating CD44+ and ALDH1+ cell formation.

GDF15 modulates cellular ROS levels to promote cancer stemness {#s2_3}
--------------------------------------------------------------

Because GDF15 modulates ROS generation (Figure [2](#F2){ref-type="fig"}), we examined whether the GDF15 contribution to cancer stemness is associated with ROS regulatory mechanisms. For this, an antioxidant agent, N-acetylcysteine (NAC), was used to reduce cellular ROS levels \[[@R35], [@R36]\]. The effect of NAC on radiosensitivity was first examined. As shown in Figure [4A](#F4){ref-type="fig"}, NAC treatment increased the surviving fraction of HNC cells by 1.6- to 2-fold after exposure to radiation at 6 Gy. To determine whether lower ROS levels could affect cancer stemness in HNC, cells were treated with NAC, and the CD44+ population was assessed by FACS. As shown in Figure [4B](#F4){ref-type="fig"}, the CD44+ population was increased after NAC treatment by 1.3- to 2.1-fold in two HNC cell lines. These results suggest that cancer stemness is associated with cellular ROS levels, and lower oxidative stress could enhance stemness.

![GDF15 modulates cellular ROS levels to promote cancer stemness\
**A.** Treatment of antioxidant agent led to radioresistance in HNC cells. After treatment of 10 μM N-acetylcysteine (NAC) for 48 h, Detroit or KB cells were subjected to serial dose of irradiation (0 to 6 Gy). Fourteen days later, the numbers of surviving cell colonies were determined (n=3). **B.** Treatment of antioxidant agent increase CD44+ cell population. After treatment of 10 μM NAC for 48 h, the OECM1 or KB cells were subjected to flow cytometry analysis for CD44+ populations. **C.** GDF15 reversed the effects of ROS in the suppression of spheroid cell formation. Detroit or KB cells were treated with H~2~O~2~ (5 μM) with or without addition of rhGDF15 (20 ng/ml) for 48 h. These cells were then incubated in the spheroid cell culture condition and assessed after 14 days (n=3). (\*: *p* \< 0.05, \*\*: *p* \< 0.01, \*\*\*: *p* \< 0.001, *t*-test).](oncotarget-08-1508-g004){#F4}

We further examined whether the ROS-cancer stemness regulatory axis can be modulated by GDF15, by using spheroid cell formation assays. As shown in Figure [4C](#F4){ref-type="fig"}, spheroid cell formation was substantially inhibited by H~2~O~2~ treatment to 78-85% compared to the controls. However, this reduction was rescued following rhGDF15 administration, with an approximately 2-fold increase in the two HNC cell lines, indicating that GDF15 can reverse the effects of ROS in the suppression of cancer stemness. Taken together, these studies suggest that GDF15 inhibits cellular ROS generation, which also promotes cancer stemness.

GDF15 regulates cellular functions via a SMAD-associated signaling pathway {#s2_4}
--------------------------------------------------------------------------

Because GDF15 is a member of the TGF-β superfamily, we examined whether GDF15 regulates cellular functions through similar downstream pathway of TGF-β. The HNC cells were first treated with a TGF-β inhibitor, LY364947 \[[@R37]\], and the GDF15 level was examined. As shown in Figure [5A](#F5){ref-type="fig"}, the GDF15 expression was reduced in a dose-dependent manner in both HNC cell lines. To confirm the downstream molecular effects of GDF15, a PAI-1 luciferase reporter assay was used, which assessed the well-known TGF-β-inducing molecule, plasminogen activator inhibitor-1 (PAI-1) \[[@R38]\]. Administration of rhGDF15 significantly increased PAI-1 luciferase activity by 8- to 13-fold in two HNC cell lines (Figure [5B](#F5){ref-type="fig"}), whereas GDF15 silencing suppressed this activation to 64% to 69% of the controls (Figure [5C](#F5){ref-type="fig"}). Furthermore, the PAI-1 expression induced by TGF-β was strongly suppressed following GDF15 silencing, by 45% to 71% in two HNC cell lines (Figure [5D](#F5){ref-type="fig"}). These results suggested that GDF15 may have a similar molecular pathway as TGF-β, and cross-talk with the TGF-β regulatory network may occur in HNC cells.

![GDF15 regulates cellular functions through similar downstream pathway of TGF-β\
**A.** GDF15 expression was reduced after treatment of TGF-β inhibitor. KB and OECM1 cells were treated with serial doses of LY364947 (5 to 20 μM) for 24 h. Cellular protein was extracted and subjected to western blot analysis to assess GDF15 protein expression. **B.** Administration of rhGDF15 increased TGF-β downstream molecule PAI-1 luciferase reporter activity. KB or Detroit cells were transfected with luciferase reporter plasmid carrying PAI-1 gene, with or without addition of rhGDF15 (20 ng/ml). After 48 h, cells were harvested for measurements of luciferase activity (n=3). **C.** Silencing rhGDF15 suppressed PAI-1 luciferase reporter activity. KB or Detroit cells were transfected with luciferase reporter plasmid carrying PAI-1 gene, with or without co-transfection of GDF15sh plasmid. After 48 h, cells were harvested for measurements of luciferase activity (n=3). **D.** PAI-1 expression induced by TGF-β was suppressed following GDF15 silencing. KB or Detroit cells were transfected with luciferase reporter plasmid carrying PAI-1 gene, with or without addition of rhGDF15 (20 ng/ml), or with or without co-transfection of GDF15sh plasmid. After 48 h, cells were harvested for measurements of luciferase activity (n=3). (\*: *p* \< 0.05, \*\*: *p* \< 0.01, \*\*\*: *p* \< 0.001, *t*-test).](oncotarget-08-1508-g005){#F5}

The SMAD family plays a key role as downstream molecules of TGF-β, which regulates the pluripotent stemness phenotype \[[@R39], [@R40]\]. We therefore examined whether GDF15 functions in HNC cells via a SMAD-associated signaling pathway. Administration of rhGDF15 significantly increased the phosphorylated forms of SMAD family proteins, with pSMAD1/5 the most prominent (Figure [6A](#F6){ref-type="fig"}). This activation of pSMAD1/5 by GDF15 was shown to be time-dependent in two HNC cell lines (Figure [6B](#F6){ref-type="fig"}). These results indicated that GDF15 functions in cells through phosphorylation of SMAD1/5 molecules to activate the downstream signaling pathway.

![GDF15 regulates cellular functions via a SMAD-associated signaling pathway\
**A, B.** Administration of rhGDF15 increased the phosphorylated forms of SMAD family proteins in HNC cells. KB or FaDu cells were treated with serial doses of rhGDF15 (0-10 ng/ml) for 15 min (A) or 5 ng/ml rhGDF15 for various times (0-120 min) (n=3). (B) The cellular proteins were extracted and subjected to western blot analysis for SMAD family protein expressions (n=3). **C.** Effects of SMAD1-siRNA on the expressions of SMAD family proteins. After transfection of SMAD1-specific siRNA or the scramble oligonucleotides in HNC cells for 48h, cellular proteins were extracted for western blot analysis. GAPDH protein was used as an internal control (n=3). **D.** Silencing SMAD1 increased ROS level in HNC cells. KB or OECM1 cells were transfected SMAD1 specific siRNA or the scramble oligonucleotides for 48 h. After treating cells with 10 μM H~2~O~2~ for 20 min, the Intracellular ROS levels were determined by DCF dye staining and analyzed with flow cytometry. **E.** Silencing SMAD1 suppressed spheroid cell formation in HNC cells. Fadu, OECM1 or KB cells were transfected SMAD1 specific siRNA or the scramble oligonucleotides for 48 h. These cells were then incubated in the spheroid cell culture condition and assessed after 14 days (n=3). **F.** The spheroid cell formation promoted by GDF15 was inhibited in SMAD knockdown HNC cells. KB or OECM1 cells were transfected SMAD1 specific siRNA or the scramble oligonucleotides for 48 h, with the addition of rhGDF15 (20 ng/ml). These cells were then incubated in the spheroid cell culture condition and assessed after 14 days (n=3). **G.** Effects of SMAD3-siRNA on the expressions of SMAD family proteins. After transfection of SMAD3-specific siRNA or the scramble oligonucleotides in HNC cells for 48h, cellular proteins were extracted for western blot analysis. GAPDH protein was used as an internal control (n=3). **H.** Silencing SMAD3 had no effect on ROS level in HNC cells. Fadu or OECM1 cells were transfected SMAD3-specific siRNA or the scramble oligonucleotides for 48 h. After treating cells with 10 μM H~2~O~2~ for 20 min, the Intracellular ROS levels were determined by DCF dye staining and analyzed with flow cytometry. **I.** Silencing SMAD3 had no significant effect on spheroid cell formation in HNC cells. Fadu, OECM1 or Detroit cells were transfected SMAD3 specific siRNA or the scramble oligonucleotides for 48 h, with the addition of rhGDF15 (20 ng/ml). After 14 days of incubation in the spheroid cell culture condition, cells were assessed for spheroid formation (n=3). (\*: *p* \< 0.05, \*\*: *p* \< 0.01, \*\*\*: *p* \< 0.001, *n.s.*: non-significance, *t*-test).](oncotarget-08-1508-g006){#F6}

We further examined whether GDF15 contributed to ROS suppression and cancer stemness through the SMAD regulatory pathway. As shown, specific knockdown SMAD1 (Figure [6C](#F6){ref-type="fig"}) substantially increased ROS levels (Figure [6D](#F6){ref-type="fig"}) and suppressed cancer stemness (Figure [6E](#F6){ref-type="fig"}). Additionally, the cancer stemness phenotype promoted by GDF15 was significantly inhibited in SMAD1 knockdown cells, as shown in two HNC cell lines (Figure [6F](#F6){ref-type="fig"}). However, knockdown SMAD3 (Figure [6G](#F6){ref-type="fig"}) had minimal effect on either ROS level (Figure [6H](#F6){ref-type="fig"}) or cancer stemness formation (Figure [6I](#F6){ref-type="fig"}). These results suggested that GDF15 regulations cell function via a via a SMAD1-associated signaling pathway.

GDF15 promotes radioresistant tumors in mice, along with SMAD activation and stemness conversion {#s2_5}
------------------------------------------------------------------------------------------------

To examine the effect of GDF15 on radioresistance in vivo, we established xenografted tumors in BALB/c nude mice. The HNC cells were first treated with or without rhGDF15 before inoculation into mice. To establish tumors in mice, two groups of mice were inoculated with rhGDF-treated cells, followed with or without radiation treatment. Another two groups were inoculated with control HNC cells, followed with or without radiation treatment. These mice were continuously monitored for up to 36 days. The tumor growth results are shown in Figure [7A](#F7){ref-type="fig"}. In the absence of radiation, there was no statistical difference in tumor growth rates between the with- and without-rhGDF15 treatment groups. After irradiation, although inhibition of tumor growth was found in both groups, tumors in the rhGDF15-treatment group grew much faster than those in the control group and were approximately 2-fold larger in size after 3 weeks (*P* = 0.016 at day 36). The results demonstrated that GDF15 confers resistance to the radiation treatment.

![GDF15 promotes radioresistant tumors in mice, along with SMAD activation and stemness conversion\
A total of 4×10^6^ KB cells, with or without pre-treatment with the rhGDF15 protein (20 ng/ml for 5 days), were subcutaneously injected into BALB/c mice (10 mice each group) in the upper portion of the hind limb. At day 14, each group was randomly divided into two groups (5 mice per group), with or without receiving 2 Gy of irradiation, followed by repeated irradiation of the same dose twice a week for a total of 8 Gy. **A.** Tumor volume was measured twice a week and calculated as (length x width x height) for 36 days. **B-D.** The tumors in the group of irradiation, either with or without pre-treatment of rhGDF15, were dissected. The protein expression levels of SMAD family molecules in the rhGDF15 treatment tumor group (B) or the control groups (C) were determined by using western blot analysis, and quantified the relative expression levels after normalized with GAPDH (D). **E.** The expression levels of ALDH1 and Nestin in tumor tissues were determined by using IHC analysis. Three tumor sections of IHC staining were shown for examples (\*: *p* \< 0.05, \*\*: *p* \< 0.01, \*\*\*: *p* \< 0.001, *t*-test).](oncotarget-08-1508-g007){#F7}

To determine whether the differential tumor growth associated with the rhGDF15 treatment was related to SMAD1 activation and stemness conversion, the xenografted tumors were dissected, and protein expression was examined using western blot and immunohistochemistry assays. The results of the two sets of xenografted tumors receiving irradiation were shown in Figure [7B-7D](#F7){ref-type="fig"}. Although there was variation between individual tumors, the pSMAD1/5 and pSMAD3 levels were generally higher in the rhGDF15-treated xenografts (Figure [7B](#F7){ref-type="fig"}) compared to the controls (Figure [7C](#F7){ref-type="fig"}), with average elevations of 2.0-fold (*P* = 0.0002) for pSMAD1/5 and 1.6-fold (*P* = 0.032) for the pSMAD3 proteins (Figure [7D](#F7){ref-type="fig"}). The results of immunohistochemistry staining for the cancer stemness marker proteins ALDH1 and Nestin in the dissected xenograft tumors are shown in Figure [7E](#F7){ref-type="fig"}. In all tumors examined, the rhGDF15-treated tumors exhibited a strong staining of these two proteins in the entire tumor mass compared to the controls. These results suggested that GDF15 conferred radioresistance in vivo through SMAD activation and stemness conversion.

DISCUSSION {#s3}
==========

Radiotherapy is an integral part of the treatment of HNC. Understanding the molecular mechanisms associated with radioresistance will help to improve the efficacy of radiotherapy. Previously, GDF15 was reported to be associated with chemo-radioresistance. The concordant findings showed an increase in GDF15 expression in irradiated oral cancer cells \[[@R41]\], an increase in plasma GDF15 levels in chemotherapeutic-resistant testicular cancer patients \[[@R42]\], and increased sensitivity to chemo-drug treatment after GDF15 knockdown in a mouse model of ovarian cancer \[[@R43]\]. However, an adverse function of GDF15 has also been reported, as GDF15 leads to cellular senescence in response to irradiation in endothelial cells \[[@R27]\]. These conflicting results may be due to differential tissue specificity, the distinct tumor status or the microenvironment that has not yet been defined. Consistent with other reports, we previously observed that GDF15 is up-regulated in HNC cell lines with high radioresistant properties \[[@R6], [@R7]\]. In the present study, we further showed that GDF15 actively contributed to radioresistance (Figure [1A-1C](#F1){ref-type="fig"}) in HNC but had no function in cell growth (Figure [1D](#F1){ref-type="fig"}), as shown in both cellular (Figure [1](#F1){ref-type="fig"}) and animal model studies (Figure [7A](#F7){ref-type="fig"}). These results demonstrate the significance of GDF15 levels on the efficacy of radiotherapy in HNC.

A model of cancer stem cells has been recently proposed to explain tumor heterogeneity. These cells have been hypothesized to possess a strong malignant potential, with high mobility, the capacity for self-renewal, and stress tolerance, which results in resistance to chemo-radiotherapy \[[@R31]--[@R33]\]. These stem types of cells are often characterized by specific surface proteins, such as CD44 and ALDH1, in head and neck tissues \[[@R31]--[@R33]\]. We therefore investigated whether GDF15 has a role in the regulation of cancer stemness in HNC. For the stemness phenotype, GDF15 has been previously reported to participate in the cellular differentiation of osteoblasts \[[@R44], [@R45]\] and to enhance tumor initiation and malignancy in multiple myeloma cells \[[@R46]\]. Consistent with these studies, we found that GDF15 promotes cancer stemness, as shown by the increase in spheroid cell formation (Figure [3I-3J](#F3){ref-type="fig"}) and invasion ability (Figure [3K-3L](#F3){ref-type="fig"}). Furthermore, these functions were accompanied by increases in the CD44+ and ALDH+ cellular populations (Figure [3A-3H](#F3){ref-type="fig"}). Therefore, GDF15 contributes to the malignancy of HNC by facilitating the conversion to the CD44+/ALDH+ stem cell-like phenotype.

Cellular ROS are the most crucial factor leading to cancer cell apoptosis after irradiation treatment, whereas low ROS is the major cause of radioresistance \[[@R29], [@R47]\]. Recently, several studies also showed a functional connection between intracellular ROS levels and the stemness status of cells. All stem cells, whether pluripotent or multipotent, appear to have lower cellular ROS levels to maintain their genomic integrity \[[@R48]\]. Similarly, cancer stem cells often display very low levels of ROS, mainly due to the increased activity of the antioxidant machinery in tumors \[[@R48], [@R49]\]. In this study, we confirmed that lower ROS levels contribute to radioresistance (Figure [4A](#F4){ref-type="fig"}) and cancer stemness (Figure [4B](#F4){ref-type="fig"}) in HNC. We further found that GDF15 reduced cellular ROS production, as shown by the positive (Figure [2C](#F2){ref-type="fig"}) and negative (Figure [2D](#F2){ref-type="fig"}) regulatory models. We also demonstrated that GDF15 was able to rescue the effects of ROS-induced cellular alteration (Figure [4C](#F4){ref-type="fig"}). Consistent with our findings, GDF15 has been reported to play a cytoprotective role against high glucose-induced cell apoptosis by inhibiting ROS production \[[@R50]\]. Thus, GDF15 contributes to radioresistance and cancer stemness in HNC through mechanisms involving in the inhibition of cellular ROS production.

Cysteine knots of the GDF15 structure represent a highly conserved sequence of the TGF-β super-family \[[@R8]--[@R9]\]. In the present study, we found that there may be cross-talk between GDF15 and the TGF-β signaling pathway in HNC cells, as shown by the regulation of a TGF-β inhibitor (Figure [5A](#F5){ref-type="fig"}), and the effects on TGF-β downstream molecules (Figure [5B-5C](#F5){ref-type="fig"}). In support of this hypothesis, the TGF-β pathway has previously been reported to possess similar functions to those we found in GDF15, as promoting the radioresistant phenotype \[[@R51]\], reducing intracellular ROS level \[[@R52]\], and contributing to cancer stemness \[[@R53]\]. Therefore, GDF15 and TGF-β may share a common signaling pathway or participate in a mutual regulatory network in cells.

The cellular functions of GDF15 are effected through various downstream molecular mechanisms. For example, GDF15 stimulated cell proliferation via PI3K/Akt and Erk signaling pathways in endothelial cells \[[@R54]\]. These Akt and Erk pathways have also been reported to induce cell growth by GDF15 in esophageal and ovarian cancers \[[@R22], [@R55]\]. GDF15 promoted metastasis through the FAK-RhoA signaling pathway in prostate cancer \[[@R56]\], whereas this metastatic function was achieved through Smad2/3 signaling in colorectal cancer \[[@R57]\]. In the present study, we found that GDF15 facilitated cancer stemness and radioresistance via activation of Smad1/5, as demonstrated in both cellular (Figure [6C-6F](#F6){ref-type="fig"}) and animal studies (Figure [7B-7D](#F7){ref-type="fig"}). Consistently, this Smad-associated pathway has been shown to be induced by GDF15 with anti-apoptotic effects in cardiomyocytes \[[@R58], [@R59]\]. Thus, GDF15 may have multiple functions in cells through distinctive signaling pathways depending on the specific tissue types.

Aggressive tumors selectively enhance particular characteristics in progressing to a therapy-refractive state. To elucidate whether GDF15 may contribute to the resistance of radiotherapy in vivo, we performed xenograft tumorigenic studies. Although tumor growth showed no difference in the absence of radiation, we found that tumors with higher GDF15 exhibited significant resistance to radiation treatment (Figure [7A](#F7){ref-type="fig"}). These results were accompanied with the augmentation of Smad protein phosphorylations (Figure [7B-7D](#F7){ref-type="fig"}) and elevated expression of the cancer stemness markers ALDH1 and Nestin (Figure [7E](#F7){ref-type="fig"}). These results were consistent with cellular findings that GDF15 rendered a more prominent effect on SMAD1/5 phosphorylation. The induction of pSMAD3 in vivo may be required by the collaboration of cellular mechanisms with tumor niche.

Taken together, our results showed that GDF15 contributed to HNC by facilitating cancer stemness. This phenotype may be achieved by regulation of intracellular ROS levels via a SMAD1-associated signaling pathway (Figure [8](#F8){ref-type="fig"}). GDF15 may serve as a predictive marker of radioresistance and a molecular target for the development of a therapeutic modality for eradiating refractory HNC.

![Diagram of the mechanism by which GDF15 contributes to radioresistance and cancer stemness through regulating ROS levels via a SMAD-associated pathway](oncotarget-08-1508-g008){#F8}

MATERIALS AND METHODS {#s4}
=====================

Cell culture and spheroid cell formation {#s4_1}
----------------------------------------

HNC cell lines, including KB, OECM1, Detroit and Fadu, were used. Cells were maintained as previously described \[[@R7], [@R60]\]. All cells were grown at 37°C in a humidified incubator containing 5% CO~2~. The spheroid cell formation assay was performed as previously described \[[@R33], [@R34]\]. Briefly, cells were cultured in a suspension (3,000-5,000 cells/ml) with F12/DMEM medium containing 1% Matrigel, N2 supplement, 10 ng/ml EGF, and 10 ng/ml bFGF. After 2 weeks, cellular spheres were visualized, and 5 independent microscopic fields were examined.

Silencing or modulation of GDF15 and SMAD molecules {#s4_2}
---------------------------------------------------

The GDF15 shRNA plasmid was constructed as previously described \[[@R61]\]. In brief, the 22 nucleotide sense and antisense hairpin oligonucleotides were designed to be complementary to the GDF15 mRNA sequence 5′-GGA- UAC- UCA- CGC- CAG- AAG- UGCG-3′. The GDF15-shRNA was then cloned into the pTopo-U6 vector plasmid. The SMAD1-specific siRNA (\#6223S) was purchased from Cell Signaling Technology (Danver, MA, USA). The plasmid transfection was performed using a Nucleofector™ Kit (Lonza, Basel, Switzerland) according to the manufacturer\'s instructions. For administration of GDF15, the recombinant human GDF15 protein (rhGDF15) (\#957-GD, R&D Systems, Minneapolis, MN) was added to the cell culture medium at 20 ng/ml for 2 to 5 days.

Analysis of CD44^+^ and ALDH1^+^ fractions by flow cytometry {#s4_3}
------------------------------------------------------------

Fluorescence-activated cell sorting (FACS) was used to isolate specific fractions of the cell population as previously described \[[@R33]\]. Briefly, the HNC cells in suspension were incubated with FITC-conjugated CD44 antibodies or the DEAB- or FITC-conjugated ALDH1 antibodies (Aldefluor kit, Stem Cell Technology, Vancouver, BC, Canada) for 60 min. After washing, the antibody-labeled cells were analyzed by flow cytometry (FACSCalibur, BD Biosciences, Franklin Lakes, NJ). The ALDH+ population was normalized to the DEAB-labeled fraction. Cells were stained with isotype-matched antibodies, and cells lacking primary antibody labeling were used as negative controls.

Determination of radiosensitivity and cell invasion ability {#s4_4}
-----------------------------------------------------------

Radiosensitivity was determined by clonogenic survival assays as previously described \[[@R62]\]. Briefly, a total of 800 cells was seeded into a 6-well plate and irradiated with serial doses of radiation (0 to 6 Gy). The cells were cultured for 12-14 days, followed by the calculation of the number of surviving colonies. The survival fraction was calculated as the number of colonies divided by the number of cells seeded times plating efficiency. Cell invasion assays were performed using BioCoat Matrigel and Transwell invasion chambers (Millipore Corp, Billerica, MA) as previously described \[[@R63]\]. The invaded cells that passed through the Matrigel-coated membranes to the reverse side were stained and photographed.

RNA extraction and RT- PCR analysis {#s4_5}
-----------------------------------

The RNA extraction, cDNA synthesis and PCR reaction were performed as previously described \[[@R64]\]. These PCR products were analyzed by 1.5% agarose gel electrophoresis. The density of each band was quantified after normalization to the actin control band using the Gel Image System (Scion Corporation, MD). All the experiments were performed duplicate for three times. The error bars shown in the relevant figures indicated the standard deviation of the quantification results in all experiments. The primers used in this study for GDF15, CD44, and actin are listed in [Supplemental Table S1](#SD1){ref-type="supplementary-material"}.

Protein extraction and western blot analysis {#s4_6}
--------------------------------------------

The protein extraction and western blot analysis were performed as previously described \[[@R65]\]. Briefly, cellular proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. The membrane was hybridized with primary antibodies and then incubated with horseradish peroxidase-conjugated secondary antibodies. The membranes were developed using an ECL developing solution (Amersham Pharmacia Biotech, Piscataway, NJ, USA) followed by autoradiography. All the experiments were performed three times independently and that typical results were shown. Using the Gel Image System (Scion Corporation, MD), the density of each band was quantified after normalization to the GAPDH control band. The error bars shown in the relevant figures indicated the standard deviation of the quantification results in all experiments. The primary antibodies used in this study, including antibodies against GDF15, CD44, ALDH1, Nestin, ph-SMAD1/5, SMAD1/5, ph-SMAD3, SMAD3, and GAPDH, are listed in [Supplemental Table S2](#SD1){ref-type="supplementary-material"}.

Measurement of reactive oxygen species {#s4_7}
--------------------------------------

Intracellular reactive oxygen species (ROS) were measured by the H~2~DCF-DA oxidation method (Invitrogen, Carlsbad, CA, USA) as previously described \[[@R34]\]. Briefly, cells were grown on plates or coverslips in HEPES buffer supplemented with H~2~DCF-DA reagent. The H~2~DCF-DA is a cell-permeable probe that is oxidized by intracellular ROS to generate fluorescent DCF. The green fluorescence of DCF was monitored by confocal laser microscopy (Zeiss Microscopy GmbH, Jena, Germany) or flow cytometric analysis (FACSCalibur, BD Biosciences, Franklin Lakes, NJ, USA). The experiments were performed three times independently. All similar results were obtained and a typical data was shown.

Detection of mitochondrial membrane potential {#s4_8}
---------------------------------------------

The mitochondrial membrane potential was determined using a MitoCapture™ Apoptosis Detection Kit (Biovision, Milpitas, CA, USA) according to the manufacturer\'s suggested protocol. The kit utilizes a cationic dye that detects changes in the mitochondrial transmembrane potential in healthy (red fluorescence) and in apoptotic (green fluorescence) cells. The intensity of cellular fluorescence was analyzed by fluorescence microscopy or by flow cytometry (FACSCalibur, BD Biosciences). The experiments were performed three times independently. All similar results were obtained and a typical data was shown.

Luciferase reporter assay for determination of TGF-β activity {#s4_9}
-------------------------------------------------------------

The TGF-β activity was measured based on its ability to induce plasminogen activator inhibitor-1 (PAI-1) expression, which was measured with a PAI-1 luciferase reporter assay (Addgene, Cambridge, MA, USA). The luciferase reporter plasmid containing PAI-1 binding sites was transfected into cells. After modulation of TGF-β or GDF15 expression by transfection of the specific shRNA or the addition of the recombinant proteins (TGF-β, \#240-B or GDF15, \#957-GD, R&D Systems, Minneapolis, MN), the luciferase activity in each experiment was determined as previously described \[[@R66]\]. All the experiments were performed triplicate for three times and the similar results were obtained. The error bars shown in the relevant figures indicated the standard deviation of a triplicate experiment.

Xenografts and in vivo tumorigenicity {#s4_10}
-------------------------------------

All animal studies were approved by the Chang Gung University Animal Care Committee. A total of 20 immunodeficient mice (BALB/cAnN.Cg-*Foxnl^nu^*/CrlNarl, 4 to 5 weeks old) were used, and the xenograft experiments were performed as previously described \[[@R7], [@R63]\]. Briefly, a total of 4 × 10^6^ KB cells, with or without pre-treatment with the rhGDF15 protein (20 ng/ml for 5days), were subcutaneously injected into BALB/c mice (10 mice each group) in the upper portion of the hind limb. At day 14, each group was randomly divided into two groups (5 mice per group), with or without receiving 2 Gy of irradiation, followed by repeated irradiation of the same dose twice a week for a total of 8 Gy. Tumor volume was measured twice a week and calculated as (length x width x height). On day 36, the mice were euthanized, and the tumors were removed for IHC and western blot analyses.

Immunohistochemical analysis {#s4_11}
----------------------------

Immunohistochemistry (IHC) was performed as previously described \[[@R67]\]. Briefly, tumors from xenografts were fixed in 10% neutralized buffered formaldehyde, embedded in paraffin, and then stained with anti-ALDH1 or anti-Nestin antibodies. The sources of these primary antibodies are listed in [Supplemental Table S2](#SD1){ref-type="supplementary-material"}. IHC analysis and color development were performed using the AEC substrate chromogen system (LSAB2 System; Dako, Agilent Technologies, Santa Clara, CA) following the manufacturer\'s instruction and a light microscope.

Statistical analysis {#s4_12}
--------------------

The *t*-test was used to analyze the statistical significance between experiments. Significance was considered when *p* value was lower than 0.05.
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